

Released: 23.09.21-...

Seite 1 von 4

Product Data Sheet

u i	Leukomed® Control
2.0 Product description	
2.1 Description	Leukomed® Control is a sterile, bacteria, virus and waterproof, transparent film dressing for the treatment of surgical and other acute wounds. It consists of a semi-permeable polyurethane film with a skin-friendly adhesive border and an absorbent hydropolymer wound pad. The transparent dressing enables visual wound inspection without removing the dressing and thus promotes undisturbed wound healing.
2.2 Intended purpose	Leukomed® Control is indicated for dry and low exuding acute wounds such as surgical wounds, superficial and partial-thickness burns, skin donor sites, lacerations and abrasions.
2.3 Instructions for use	Yes
2.4 Warnings and precautions for use	 Leukomed® Control is for single use only. Do not use if the pouch is already open or damaged as the sterility of the dressing is guaranteed only when the pouch is unopened and undamaged prior to use. Leukomed® Control may be used on infected wounds only after consulting a healthcare professional. Do not use on patients with a known sensitivity to glycerine or hydrogels. In case of intolerance, remove the dressing and gently cleanse the wound with water or sterile saline solution. The hydropolymer pad may be moistened with sterile saline solution for easier removal, if required. Should gel fragments remain in the wound bed after removing the dressing, these may be removed by irrigation with sterile saline solution or water. During the body's normal healing process, non-viable tissue is removed from the wound, which could initially make the wound appear larger. If the wound continues to grow larger after the first few dressing changes, consult a healthcare professional. Because Leukomed® Control creates an environment that favours the growth of new blood vessels, the delicate newly formed blood vessels may occasionally produce blood-stained wound fluid. Monitor the wound carefully. Leukomed® Control can remain in situ for up to 14 days, depending on the wound condition. The total duration of contact is 30 days if the treatment involves consecutive application of individual dressings and if the clinical conditions allow. No data are available that support the use of topical medicinal preparations in conjunction with Leukomed® Control. For external use only.
2.5 Contraindications	Leukomed® Control is not indicated for surgical implantation, to control heavy bleeding, for third-degree burns or for the placement inside deep cavities or sinuses. Not suitable for use under a compression bandage or for radiation therapy.



Released: 23.09.21-... Seite 2 von 4

2.7 Duration of application

Leukomed® Control can remain in situ for up to 14 days, depending on the wound condition

5x7 cm; 7x10 cm; 8x15 cm: 2 3 5 10x24 cm; 10x35 cm: 1 Composition 2.8 2 3 5 Designation **Description** % of final product (incl. no. in drawing) Backing (1) Polyurethane film 5 Adhesive (2) Polyacrylate adhesive 10 Wound Pad (3) Viscose/Polypropylene 82 non-woven Release liner white (4) siliconized LDPE 1,5 Rlease liner clear (5) Option 1: siliconized PET 1,5 Option 2: siliconized HDPE Size/ Color Per folding box Per shipper **Product code** 5 cm x 7 cm 73230-00 10 28 7 cm x 10 cm 10 20 73230-01 2.9 **Product range** 8 cm x 15 cm 10 20 73230-02 10 cm x 24 cm 5 20 73230-03 10 cm x 35 cm 5 10 73230-05 2.10 Storage conditions Dry, clean, below 25°C/77°F and without exposure to direct sunlight 2.11 Shelf life/ Storage time 3 years



Released: 23.09.21-... Seite 3 von 4

2.12 Sterilization	Gamma radiation according to (DIN EN) ISO 11137-1, -2, -3		
2.13 Key quality parameters	Characteristic	Method	Target
	Adhesion to steel (final product)	Essity internal	2.20 N/cm
	MVTR	DIN EN 13726-1	> 800 g/m ² *24h
	Water activity	supplier internal	45-70%
	Saline uptake	supplier internal	1000-2000%
	Gel coat weight	supplier internal	1.0-1.4 kg/m ²

3.0 Chemical substances of special concern to Essity

Essity has defined chemical substances that are of special concern and are subject to specific restrictions. A reference to the list of substances can be found in Annex A2 via the following link www.essity.com/gss

Deviations are covered in 3.1 Components.

Raw materials used in product formulation

Substance	Included in formulation
natural rubber Latex	No
Lanolin and its derivatives	No
Colophony	No
Colophony derivatives	No
Bisphenol A (BPA)	No
Polyvinylchloride (PVC)	No
Methylmethacrylate	No
Butylacrylate	No
Microplastics (<5 mm)	No
Nanoparticles	No
Fragrance/parfum	No
Antibiotics	No
Triclosan	No
Chlorhexidine	No
Polyhexanide	No

3.1 Components

Raw materials used in the packaging

Substance	Included in formulation
Polyvinylchloride (PVC)	No
Natural rubber latex	No
Recycled material	Partly used for shipper case

Raw materials used in the product formulation and in the packaging may contain small amounts of the substances listed above and not marked as included in formulation as well as amounts of other substances not listed above. As trace level analysis is not performed for each batch BSN medical GmbH cannot provide proof of absence.



Released: 23.09.21-... Seite 4 von 4

History

Version / Date	Page / Item	Description of Change
01 / 28.09.2015	All	Set up new document
02 / 10.04.2019	All	General revision according to current product family
		description
03 / 15.09.2021	All	General revision, update to new template
	Page 1 / Item 2.7	Duration of use is extended to 14 days